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Abstract
Background: Treatment services to patients with substance use disorders (SUDs), including those mandated to
treatment, needs to be evaluated and evidence based. The Norwegian Municipal Health Care Act calls for mandated
treatment for persons with “severe and life-threatening substance use disorder” if these individuals are not otherwise
willing to be voluntarily treated and consequently risk their lives over drug use. This study aims to examine substance
use–related outcomes at 6 months following inpatient treatment and to analyse factors associated with improved
outcomes and abstinence.
Method: This prospective study followed 202 hospitalized patients with SUD who were admitted voluntarily (VA; n= 137)
or compulsorily (CA; n = 65). The European Addiction Severity Index was used at baseline and at follow-up to
assess socio-demographic and substance use variables. Regression analysis was conducted to investigate factors
associated with abstinence at 6 months of follow-up.
Results: The frequency of use of a preferred substance showed marked improvement for both VA and CA patients
(61 and 37 %, respectively) at follow-up. Seventy-five percent of VA patients using amphetamine reported improvement
compared to 53 % of CA patients. At follow-up, the CA group continued to have a higher rate of injection use. The CA
group had experienced higher rates of overdose in the past 6 months and lower abstinence rates (24 % versus 50 %) at
follow-up. A lower severity of drug use at intake (non–injection drug use), voluntary treatment modality, and higher
treatment involvement during follow-up all were significant factors associated with abstinence at 6 months after
treatment.
Conclusion: Voluntary treatment for SUD generally yielded better outcomes; nevertheless, we also found improved
outcomes for CA patients. It is important to keep in mind that in reality, the alternative to CA treatment is no treatment at
all and instead a continuation of life-threatening drug use behaviours. Our observed outcomes for CA patients support
the continuation of CA treatment.
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Background
Substance use disorder (SUD) is a chronic relapsing
disorder better managed by ongoing monitoring and
extended services than by acute care model treatment
approaches [1, 2]. Improved life functioning and quality
along with substance use reduction are increasingly rec-
ognized as appropriate measures of effective addiction
treatment outcomes [3].
It is generally accepted that external pressure has an
influence on treatment seeking, and a high proportion of
SUD patients may not have received treatment without
pressure from friends, family, or the courts, which could
be considered informal coercion [4]. In many countries,
formal coercion is also an option when voluntary treat-
ment has proven unsuccessful, but the compulsory
hospitalization of SUD patients has been a controversial
option [5]. This controversy sometimes centres on eth-
ical or due process issues associated with use of forced
entry into treatment but also often focuses on debate
about the effectiveness of such compulsory treatment
because motivation for change is likely to be low among
those coerced into treatment [6]. Research into the ef-
fectiveness of compulsory treatment has yielded a mixed
and inconclusive pattern of results, in part because of
considerable differences in contexts and regulations
around it [7, 8]. In Norway, the Social Services Act of
1993 allowed compulsory admissions to the hospital for
persons with severe and life-threatening substance use.
In 2012, this law was replaced by the Norwegian Munici-
pal Health Care Act, in which § 10.2 (NMHCA) sanctions
involuntary interventions for non-psychotic adult patients
with SUDs [9]. The Act covers an option for retention (up
to 3 months) when the health of the patient is seriously at
risk because of extensive, prolonged substance use and
voluntary efforts have proven insufficient. Despite over
20 years of practice under these compulsory treatment
acts, little is known about the outcomes for the patients,
as this question has not been previously addressed.
Inpatient SUD treatment is generally an effective ap-
proach that can initiate changes in behaviour and increase
motivation for a lifetime of recovery rather than a situ-
ation dominated by drug use [10]. Although most of the
questions of concern for inpatient treatment have been
about the duration of effects, there are calls for research
that examines which subpopulations of patients benefit
most from various inpatient treatment modalities [11].
Assessments of such treatment effects should not only
take place at treatment completion or when patients are
transferred from one treatment phase to another but
also after a certain time following a completed treatment
episode. Especially for compulsory admitted patients
(CA), it is important to examine the outcomes at some
point after the initial treatment episode has ended to in-
vestigate the “real” outcomes following treatment.
Aims
The aims of this study were to examine treatment out-
comes in terms of drug use at the 6-month follow-up of
inpatient SUD treatment, as follows: (1) Describe drug
use and drug use patterns at the 6-month follow-up; (2)
investigate changes in drug use at follow-up compared
with intake to treatment, by voluntary and compulsory
treatment status; and (3) analyse factors associated with
abstinence and improvement in drug use at the 6-month
follow-up.
Methods
Participants
A total of 326 SUD patients, either voluntarily admitted
(VA) or CA, were invited to participate in this prospect-
ive study. Participants were eligible for this study if they
were >18 years of age, had a SUD, could understand
Norwegian, and were admitted at least 3 weeks prior to
study inclusion, allowing them enough time for detoxifi-
cation and stabilization before giving informed consent.
According to the inclusion criteria, 228 were eligible, but
26 patients refused to participate. Of the 202 patients en-
rolled at baseline (65 CA and 137 VA), 123 (61 %) were
interviewed at 6 months of follow-up. Because of limita-
tions in funding and the large geographical uptake area,
CA patients were prioritized for follow-up (82 % CA
patients versus 59 % VA patients were included) because
the CA patients were less represented in the sample at
baseline. Thus, the higher loss to follow-up in the VA
group was for mainly administrative and logistic reasons.
The further attrition analysis showed no other differences
between those who were and were not reached at follow-
up in terms of demographic data, severity scores, or length
of stay in the initial treatment episode.
Data collection
Recruitment for this prospective study continued con-
secutively between January 2009 and May 2011 from
three different publicly funded treatment centres in the
southeastern part of Norway. SUD patients, CA or VA,
were treated together in the same mixed-gender wards.
The treatment wards had multidisciplinary staff, includ-
ing psychiatrists, psychologists, social workers, occupa-
tional therapists, specialized nurses, and other trained
staff. The centres offered treatment for patients with pri-
mary SUD, often combined with mental disorders.
Treatment included assessments of somatic and mental
health along with pharmacotherapy, cognitive milieu
therapy, and individual motivation enhancement. Before
study inclusion, the patients were either detoxified, which
was verified by negative urine tests for alcohol, opioids,
central stimulants (amphetamines, methamphetamines,
and cocaine), benzodiazepines, and cannabis; or they spent
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a minimum of 3 weeks days in detoxification to establish
baseline values not influenced by withdrawal symptoms.
No standard aftercare service was routinely provided
by the wards themselves, but individual aftercare plans
were made according to clinical needs in cooperation
with primary care services or with social services. All
patients were diagnosed based on a structured interview
and examination in accordance with the International
Classification of Diseases and Related Health Problems,
10th Revision (ICD-10). Follow-up interviews were per-
formed 6 months after discharge from the hospitals and
took place between July 2009 and December 2011, which
included extensive travelling for the data collection
team. Because patients came from all over the country
(particularly the CA group), a team of dedicated project
staff attempted to contact all patients directly by phone,
mail, or post. In some cases, patients were found to be
in prison or in inpatient treatment institutions, and
arrangements were made to meet them there.
Instruments and measure
The Mini International Neuropsychiatric Interview, ver-
sion 5.0, was conducted at baseline to confirm the SUD
diagnosis [12]. To assess demographics and severity of
substance use variables, the most commonly used meas-
ure within addiction treatment research was used; the
European Addiction Severity Index (EuropASI) [13, 14].
The EuropASI is a structured interview performed by
trained and certified staff. Variables from the EuropASI
used in the analyses included severity of substance use
variables, such as frequency of substance use in the last
6 months (0 = never used; 1 = sometimes, but less than
2–3 times a month; 2 = 1–3 days a week; 3 = everyday use)
and whether the patient had injection use or overdoses in
the last 6 months. Whether patients were abstinent or
not, was determined according to self-reported alcohol
and drug use for the 30 days prior to the follow-up inter-
view, i.e., the abstinent group had no alcohol or drug use
during this period. The patients also disclosed their pre-
ferred substance of use (alcohol, amphetamine, cannabis,
opioids, or benzodiazepines) and were assessed whether
they had had suicidal attempts in their lifetime. Other var-
iables used were type of admission to inpatient treatment
(CA or VA).
The same questionnaire was used at follow-up. In
addition, time in a controlled environment as defined by
the EuropASI as days in jail or SUD treatment in the
30 days before follow-up was used.
Analysis and statistical methods
Continuous variables are reported as means and standard
deviations. Categorical variables are reported as frequen-
cies. Changes in frequency of the preferred substance of
use at the 6-month follow-up were performed using the
matched-pairs Wilcoxon signed-rank test for the CA and
VA patients separately. Thus, it was possible to decide
whether the use of these substances had increased, de-
creased, or remained constant over time. Also changes in
amphetamine and cannabis use are described because only
these two single substances were reported as having been
used as preferred substances by a sufficient number of
patients to justify an analysis. Bivariate logistic regression
was used to compare severity variables between groups at
6 months after treatment. Logistic regression was also
used to examine predictors of abstinence at the follow-up.
From bivariate analyses, variables with a p value < 0.2 were
included in the multivariate analysis [15]. Results are pre-
sented as odds ratio (ORs) with 95 % confidence interval
(CIs). P values < 0.05 were considered statistically signifi-
cant. Analyses were performed with the Statistical Package
for the Social Sciences software, version 21.0 (SPSS Inc.,
Chicago, IL, USA).
Results
The 202 participants at baseline had a mean age of
30 years, and 34 % were women (Table 1). The proportion
of CA patients was 32 % (65) versus 68 % (137) VA. All
patients met the ICD-10 criteria for SUD; the majority
had a drug use disorder (83 %). Injection use 6 months
prior to hospitalization was reported by 54 % of the
participants.
Table 1 Baseline socio-demographic variables for patients
included at baseline (202) and those reached at follow-up (123)
[N (%) or mean (SD)]
Variables All patients,
N = 202
Follow-up
sample, N = 123
Mean age, years 30.0 (8.9) 30.4 (9.8)
Female 68 (34) 47 (39)
Education, years 10.8 (1.9) 10.8 (2.1)a
Relationship status, singleb 136 (69) 84 (68)c
Main diagnosis
Alcohol use disorder (AUD)
or AUD with co- occurring drug
use disorders
34 (17) 20 (16)
Drug use disorder 168 (83) 103 (84)
Severity scores
Injection used 105 (54) 71 (60)e
Duration of most problematic
substance use, years
11.1 (7.6) 11.6 (7.6)f
Suicidal attempts – lifetime
prevalenceg
94 (49) 60 (51)h
Treatment variables
Time in treatment, days 57 (26) 58 (26)
Compulsorily admitted 65 (32) 51 (42)
aN = 117 ;bN = 198; cN = 121; dN = 195; eN = 119; fN = 117; gN = 191; hN = 117
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At the 6-month subsequent treatment, there was an
11 % reduction in injection use from baseline to follow-
up (55 to 44 %, p = 0.001, Wilcoxon signed-rank test).
The reductions were 10 % (from 71 to 61 %) for the CA
group and 16 % (from 47 to 31 %) for the VA group.
A total of 31 CA patients (61 %) reported injecting
drugs compared to 22 VA patients (31 %) (OR = 3.38,
95 % CI = 1.59–7.20, p = 0.001) (Table 2). Only one VA
patient (1 %) reported an overdose during follow-up,
compared to 11 CA patients (22 %) (OR = 19.25, 95 % CI
= 2.40–154.65, p = 0.001). Compared to CA patients, twice
as many VA patients reported total abstinence from all
substances in the 30 days prior to the interview (50 %
versus 24 %; OR = 0.31, 95 % CI = 0.14–0.68, p = 0.013).
Both groups had a significant reduction in the frequency
of the preferred substance (61 % of VA patients and 37 %
of CA patients) (Table 3). Amphetamine and cannabis
were significantly less used in both groups at the follow-
up. However, 75 % of VA patients using amphetamine
reported improvement compared to 53 % of CA patients.
Improvement in cannabis use was quite similar for both
CA and VA patients (62 and 61 %) (Table 3).
At follow-up, 48 of 123 (39 %) participants reported
having abstained from all substances during the previous
30 days. However, 19 of 36 (53 %) and 7 of 12 (58 %) in
the VA and CA groups, respectively, had been in a con-
trolled environment for the majority of the 30 days be-
fore the follow-up, which for most of them meant
inpatient SUD treatment. Thus, we hereafter also refer
to this variable as “treatment involvement”.
Route of drug administration at intake (injection drug
use), treatment modality, and treatment involvement
during follow-up were all significant factors explaining
abstinence at follow-up (Table 4). In this analysis we sys-
tematically included and controlled for variables that
was found to be significantly different between groups at
baseline [16]. The multivariate analysis retained days in
a controlled environment (OR = 1.08, 95 % CI = 1.04–
1.12, p < 0.001), non-injection use at baseline (OR = 3.36,
95 % CI = 1.32–8.56, p < 0.011), and voluntary admission
(OR = 3.40, 95 % CI = 1.29–8.93, p < 0.013) as factors
positively associated with abstinence at follow-up.
Discussion
The majority of SUD patients approaching inpatient
treatment engaged in injecting behaviour prior to base-
line treatment and had many years of drug use experi-
ence, indicating a severe SUD level. At 6 months of
follow-up, injection use showed improvement in both
groups. Self-reported improvements regarding frequency
of use of the “preferred substance” were observed for the
majority of VA patients and more than one third of CA
patients. Non-injection behaviour prior to treatment
along with treatment involvement and voluntary treat-
ment modality were positively associated with achieving
abstinence at follow-up.
The SUD outcome measures (frequency of substance
use, injection use, and overdoses) at 6 months of follow-
up showed positive results for these SUD patients. This
outcome indicates long-lasting consequences of the
index treatment beyond hospitalization. Significantly
more VA than CA patients reported improved outcomes.
US studies have shown better outcome for CA than VA
patients owing to better retention and hence longer pe-
riods in a controlled regime [17]. In contrast, compari-
sons of CA and VA patients in Swedish settings have
shown no difference between these two groups regarding
outcomes. The quality of the treatment provided seems
to be a crucial factor because motivation is mutable and
can be developed or diminished by the quality of sup-
port and services offered to patients, which is especially
important to CA patients [18]. Structured, integrated,
and long-term treatments that consider patient perspec-
tives and needs may provide superior benefits compared
to a plain “holding” strategy [17, 19].
In Norway, injection drug use is more common in CA
compared to VA patients [16]. In the current work, sig-
nificantly more CA than VA patients had been injecting
illicit drugs at 6 months of follow-up (61 vs. 31 %). Simi-
lar high rates of injection use at follow-up have also
been observed previously among injection substance
users (up to 75 %) [20–22]. The continued high rate of
injection use post treatment in the CA group is a chal-
lenge for treatment providers, and it is a concern that
change in injection behaviour did not improve more fol-
lowing long-term inpatient treatment. Injection along
with severe SUD provides a serious risk for overdose
[23]. A long-term improvement and harm reduction for
SUD patients requires addressing and changing injection
behaviour, which should be an explicit goal during treat-
ment. The time available in inpatient treatment is a win-
dow of opportunity that should be maximized in terms
of prevention, intervention, testing, and vaccination for
Table 2 Outcome measures at 6 months of follow-up for
compulsorily and voluntarily admitted SUD patients
Variable Group N (%) ORb 95 % CI P value
Patients with injection
drug use (%)a
CA 31 (61) 3.38 1.59–7.20 0.001
VA 22 (31) 1.00d
Patients with overdose
during follow-up (%)c
CA 11 (22) 19.25 2.40–154.65 <0.001
VA 1 (1) 1.00 d
Patients with abstinence
30 days before
follow-up (%)
CA 12 (24) 0.31 0.14–0.68 0.013
VA 36 (50) 1.00 d
aN = 121
bOR obtained from logistic regression
cN = 122
d = reference group
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blood-borne viruses and for overdose prevention train-
ing. Specific overdose preventive programs could include
aspects of identification and risk factors of overdose,
recognize signs of an overdose and how to respond ap-
propriately; call ambulance, provide rescue breathing
and administer naloxone if available. Distribution of
naloxone rescue kits together with overdose prevention
training, to drug users prior to discharge from drug
treatment would empower the drug user. This would be
a way for clinicians to introduce a preventive message
and harm reduction interventions prior to discharge, in
a patient centered fashion.
The importance of assessing treatment outcome by prin-
cipal drug of concern has been highlighted [24]. Accord-
ingly, our results showed solid reductions in frequency of
preferred drug use at follow-up compared to baseline for
all patients. One explanation for this outcome might be
that in Norway, the treatment for most patients in the CA
group is integrated with that of the VA group, which is
considered to be an approach that would benefit CA pa-
tients in particular because they then receive the treatment
approaches that any other SUD patient does during treat-
ment [25]. In addition, being in a shared environment with
VA patients would likely “normalize” the treatment experi-
ence for CA patients.
In a US study, Brecht et al. performed a simple compari-
son between CA and VA patients in regards to different
outcomes for coerced treatment for methamphetamine
abuse and found no significant differences [26]. Although
our study showed that the VA patients were somewhat
Table 3 Perceived changes in frequencies of substance use at 6 months of follow-up (from baseline)
Mean score baselinea Mean score follow-upa Deterio-ration No change Improved P valueb
Frequency of preferred
substancec (n = 120)
VA (71) 2.7 1.5 4 (5 %) 24 (34 %) 43 (61 %) <0.001
CA (49) 2.8 2.2 2 (4 %) 29 (59 %) 18 (37 %) <0.001
Cannabisd (n = 49) VA (28) 2.7 1.5 3 (11 %) 8 (28 %) 17 (61 %) <0.001
CA (21) 2.6 1.5 2 (9 %) 6 (28 %) 13 (62 %) 0.006
Amphetamined (n = 43) VA (24) 2.8 1.2 0 (0 %) 6 (25 %) 18 (75 %) <0.001
CA (19) 2.5 1.7 2 (10 %) 7 (37 %) 10 (53 %) 0.026
aThe ordinal ASI scale (frequency of use in the last 6 months) was defined as follows: 0 = never used; 1 = sometimes, but less than 2–3 times a month; 2 = 1–3 days a
week; 3 = everyday use)
bP value from Wilcoxon signed-rank test
cPreferred substance according to the ASI interview
dSub-analyses of specific preferred drug if more than 40 patients reported preference for this substance
Table 4 Predictors of abstinence from baseline to follow-up (N = 123 patients)
Parameter Bivariate analysis P valuea Multivariate analysis P
valuebOR (95 % CI) OR (95 % CI)
Age 1.02 (0.98–1.06) 0.267 –
Female 1.27 (0.60–2.67) 0.528 –
Education (years) 1.05 (0.88–1.25) 0.619 –
Relationship status, single 0.56 (0.25–1.30) 0.175 0.45 (0.17–1.25) 0.127
Main diagnosis 1.23 (0.45–3.34) 0.687 –
Severity scores
Non-injection use 2.59 (1.21–5.54) 0.014 3.36 (1.32–8.56) 0.011
Years of using most problematic substance 1.01 (0.96–1.1) 0.699 –
Overdoses 0.92 (0.43–1.97) 0.840 –
Suicide attempts lifetime 1.32 (0.63–2.79) 0.456
Treatment variables
Days in treatment 1.00 (0.98–1.02) 0.511 –
Voluntary treatment 0.31 (0.14–0.68) 0.004 3.40 (1.29–8.93) 0.011
Follow-up variables
Abstinence at follow-up 1.51 (0.63–3.66) 0.356 –
Time in a controlled environment (days)c 1.07 (1.03–1.10) <0.001 1.08 (1.04–1.12) <0.001
aP value obtained from bivariate logistic regression
bP value obtained from multivariable logistic regression; multivariable analysis included variables with p values <0.20 in bivariate analyses
cTime in controlled environment in last 30 days before follow-up interview
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better off at 6 months after treatment, there were marked
improvements in amphetamine use also in the CA group
(53 % reported reduction in the frequency of use). In
terms of cannabis use, the two groups had a similar reduc-
tion; about half of both groups had reduction of use. Thus,
the results suggest optimism for individuals and psycho-
social intervention outcomes for SUD treatment in both
VA and CA patients. In addition, having an aftercare plan
and evaluating treatment outcomes in terms of appropri-
ate patient-centred measures, such as quality of life, might
become increasingly important when combinations of in-
terventions are to be evaluated for chronic conditions
within a long-term perspective [27, 28].
It has been highlighted that it remains largely unclear to
what extent many of the commonly employed methods
for getting people into treatment may be detrimental to
the treatment process and longer-term outcomes [19].
Our results at follow-up showed a negative association
between CA and abstinence when compared with VA.
Nevertheless, within the CA group, we found that 24 % of
patients achieved abstinence.
In the acute phase of CA treatment, the main target
for the retention of patients is to provide life-saving
treatment; in the longer term, the aim is to reduce drug
use and increase motivation for further treatment, leading
to long-term recovery [29]. Thus, our findings provide
somewhat mixed results particularly regarding CA pa-
tients because many had less favourable drug use out-
comes at 6 months of follow-up compared to VA patients.
Still, we are optimistic that by integrating the results of
our research it may help further improve abstinence rates
at 6 months among CA patients.
However, the comparison between the VA and CA
groups is somewhat unfair in this respect because the mo-
tivation for change was likely very different at treatment
intake. Hence, the positive outcomes for the CA group
need to be interpreted against this background. The only
real alternative to CA treatment is no treatment at all.
Methodological considerations
This study had some limitations that should be considered
when interpreting the results. Caution should be taken in
generalizing these findings on the basis of a relatively small
sample at follow-up. Attrition rate at follow-up was larger
in the VA group, which could have biased results toward a
better outcome for the VA responders. However, the attri-
tion analyses of background data for the VA group showed
no difference between those reached at follow-up com-
pared with non-responders. It is not ethical to randomize
to voluntary treatment patients that are deemed in need
for compulsory treatment. Conversely; patients that are
not deemed in need for compulsory treatment should not
be randomized to a CA group. Thus, there were no ran-
dom allocations of the participants in this study.
This study is based on self-reported data. Although the
dataset is likely representative for hospitalized SUD popu-
lations in Norway, particularly the observed outcomes for
CA patients may vary considerably across settings and
regions with differing laws regarding compulsory SUD
treatment.
This study was, to our knowledge, the first in Norway
to provide follow-up outcomes in patients hospitalized
by CA with a comparison to VA patients.
Conclusion
We showed that specialized SUD treatment provides im-
provement in drug use outcomes overall at 6 months of
follow-up. Although voluntary treatment generally showed
better outcomes, we found encouraging outcomes also
among CA patients. It is important to keep in mind that
the alternative to CA treatment in reality is no treatment
at all and instead a continuation of life-threatening drug
use behaviours. Therefore, we ideally should judge CA
outcomes as contrasting with “no treatment”. Still, the re-
sults for CA patients that are comparable with those for
VA treatment provide support for the continuation of CA
treatment.
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